Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients

Haemostasis. 1975;4(2):94-100. doi: 10.1159/000214092.

Abstract

In a prospective randomised trial, three groups of 20 patients each were compared. A first group served as a control, a second group received dipyridamole and acetylsalicylic acid and a third group received low doses of heparin. The incidence of deep vein thrombosis determined by the 125I-fibrinogen test was 40% in the first group, 50% in the second group, and 5% in the third group. The differences between the heparin group and the two other groups are statistically significant. No wound complication and no haematoma at the injection site occurred.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aspirin / pharmacology*
  • Aspirin / therapeutic use
  • Blood Platelets / metabolism
  • Dipyridamole / pharmacology*
  • Dipyridamole / therapeutic use
  • Female
  • Heparin / administration & dosage
  • Heparin / pharmacology*
  • Heparin / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Platelet Aggregation / drug effects
  • Postoperative Complications / prevention & control*
  • Prospective Studies
  • Thromboembolism / prevention & control*

Substances

  • Dipyridamole
  • Heparin
  • Aspirin